secwatch / observer

8-K filed May 27, 2026, 4:45 PM ET CIK 0002044820

other material confidence high sentiment neutral materiality 0.50

VistaOne L.P. reports $23.6M unit sale, NAV per class, and $46.9M repurchase

VistaOne, L.P.

Sold 187,162 Class B, 500,054 Class I, and 79,673 Class S units for aggregate $23.6M.
Transactional NAV per unit as of April 30: Class A-I $30.88, Class E $32.29, Class R $25.17.
Repurchased 1,538,720 units at avg. $30.48/unit for total $46.9M.
Expense support agreement with Manager; reimbursement period expected no earlier than Oct 1, 2026.

item 3.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0002044820-26-000023
form_type: 8-K
ticker: null
cik: 0002044820
company_name: VistaOne, L.P.
filed_at: 2026-05-27T20:45:46+00:00
discovered_at: 2026-05-27T20:47:00.334570+00:00
generated_at: 2026-05-27T20:49:50.352244+00:00
sec_items: ["3.02", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0002044820-26-000023
json_url: https://secwatch.observer/filing/0002044820-26-000023.json
markdown_url: https://secwatch.observer/filing/0002044820-26-000023.md
text_url: https://secwatch.observer/filing/0002044820-26-000023.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2044820/000204482026000023/0002044820-26-000023-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2044820/000204482026000023/ck0002044820-20260520.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BUKS

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

BUTLER NATIONAL CORP June 1, 2026, 12:41 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ONCY

Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned

ONCOLYTICS BIOTECH INC June 1, 2026, 9:06 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CLIR

ClearSign Technologies prices 777,780-share public offering at $4.33/share for ~$3.37M gross proceeds

ClearSign Technologies Corp June 1, 2026, 8:30 AM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

RDAC

Shareholders approve SPAC extension to Oct 15, 2027; ~1.9M shares redeemed

Rising Dragon Acquisition Corp. June 1, 2026, 6:08 AM ET other_material Items 1.01, 5.03, 5.07, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0002044820-26-000023

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.